AAAAAA

   
Results: 1-10 |
Results: 10
Discovery of human CCR5 antagonists containing hydantoins for the treatment of HIV-1 infection
Authors: Kim, D Wang, LP Caldwell, CG Chen, P Finke, PE Oates, B MacCoss, M Mills, SG Malkowitz, L Gould, SL DeMartino, JA Springer, MS Hazuda, D Miller, M Kessler, J Danzeisen, R Carver, G Carella, A Holmes, K Lineberger, J Schleif, WA Emini, EA
Citation: D. Kim et al., Discovery of human CCR5 antagonists containing hydantoins for the treatment of HIV-1 infection, BIOORG MED, 11(24), 2001, pp. 3099-3102
Design, synthesis, and SAR of heterocycle-containing antagonists of the human CCR5 receptor for the treatment of HIV-1 infection
Authors: Kim, D Wang, LP Caldwell, CG Chen, P Finke, PE Oates, B MacCoss, M Mills, SG Malkowitz, L Gould, SL DeMartino, JA Springer, MS Hazuda, D Miller, M Kessler, J Danzeisen, R Carver, G Carella, A Holmes, K Lineberger, J Schleif, WA Emini, EA
Citation: D. Kim et al., Design, synthesis, and SAR of heterocycle-containing antagonists of the human CCR5 receptor for the treatment of HIV-1 infection, BIOORG MED, 11(24), 2001, pp. 3103-3106
Combinatorial synthesis of CCR5 antagonists
Authors: Willoughby, CA Berk, SC Rosauer, KG Degrado, S Chapman, KT Gould, SL Springer, MS Malkowitz, L Schleif, WA Hazuda, D Miller, M Kessler, J Danzeisen, R Holmes, K Lineberger, J Carella, A Carver, G Emini, EA
Citation: Ca. Willoughby et al., Combinatorial synthesis of CCR5 antagonists, BIOORG MED, 11(24), 2001, pp. 3137-3141
1,3,4-trisubstituted pyrrolidine CCR5 receptor antagonists. Part 2: Lead optimization affording selective, orally bioavailable compounds with potent anti-HIV activity
Authors: Hale, JJ Budhu, RJ Holson, EB Finke, PE Oates, B Mills, SG MacCoss, M Gould, SL DeMartino, JA Springer, MS Siciliano, S Malkowitz, L Schleif, WA Hazuda, D Miller, M Kessler, J Danzeisen, R Holmes, K Lineberger, J Carella, A Carver, G Emini, E
Citation: Jj. Hale et al., 1,3,4-trisubstituted pyrrolidine CCR5 receptor antagonists. Part 2: Lead optimization affording selective, orally bioavailable compounds with potent anti-HIV activity, BIOORG MED, 11(20), 2001, pp. 2741-2745
Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 1: Discovery and initial structure-activity relationships for 1-amino-2-phenyl-4-(piperidin-1-yl)butanes
Authors: Dorn, CP Finke, PE Oates, B Budhu, RJ Mills, SG MacCoss, M Malkowitz, L Springer, MS Daugherty, BL Gould, SL DeMartino, JA Siciliano, SJ Carella, A Carver, G Holmes, K Danzeisen, R Hazuda, D Kessler, J Lineberger, J Miller, M Schleif, WA Emini, EA
Citation: Cp. Dorn et al., Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 1: Discovery and initial structure-activity relationships for 1-amino-2-phenyl-4-(piperidin-1-yl)butanes, BIOORG MED, 11(2), 2001, pp. 259-264
Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 2: Structure-activity relationships for substituted 2-aryl-1-[N-(methyl)-N-(phenylsulfonyl) amino]-4-(piperidin-1-yl)butanes
Authors: Finke, PE Meurer, LC Oates, B Mills, SG MacCoss, M Malkowitz, L Springer, MS Daugherty, BL Gould, SL DeMartino, JA Siciliano, SJ Carella, A Carver, G Holmes, K Danzeisen, R Hazuda, D Kessler, J Lineberger, J Miller, M Schleif, WA Emini, EA
Citation: Pe. Finke et al., Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 2: Structure-activity relationships for substituted 2-aryl-1-[N-(methyl)-N-(phenylsulfonyl) amino]-4-(piperidin-1-yl)butanes, BIOORG MED, 11(2), 2001, pp. 265-270
Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 4: Synthesis and structure-activity relationships for 1-[N(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-(4-(N-(alkyl)-N- (benzyloxycarbonyl)amino)piperidin-1-yl)butanes
Authors: Finke, PE Oates, B Mills, SG MacCoss, M Malkowitz, L Springer, MS Gould, SL DeMartino, JA Carella, A Carver, G Holmes, K Danzeisen, R Hazuda, D Kessler, J Lineberger, J Miller, M Schleif, WA Emini, EA
Citation: Pe. Finke et al., Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 4: Synthesis and structure-activity relationships for 1-[N(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-(4-(N-(alkyl)-N- (benzyloxycarbonyl)amino)piperidin-1-yl)butanes, BIOORG MED, 11(18), 2001, pp. 2475-2479
Effect of iron deficiency on placental transfer of iron and expression of iron transport proteins in vivo and in vitro
Authors: Gambling, L Danzeisen, R Gair, S Lea, RG Charania, Z Solanky, N Joory, KD Srai, SKS McArdle, HJ
Citation: L. Gambling et al., Effect of iron deficiency on placental transfer of iron and expression of iron transport proteins in vivo and in vitro, BIOCHEM J, 356, 2001, pp. 883-889
The effect of ceruloplasmin on iron release from placental (BeWo) cells: Evidence for an endogenous Cu oxidase
Authors: Danzeisen, R Ponnambalam, S Lea, RG Page, K Gambling, L McArdle, HJ
Citation: R. Danzeisen et al., The effect of ceruloplasmin on iron release from placental (BeWo) cells: Evidence for an endogenous Cu oxidase, PLACENTA, 21(8), 2000, pp. 805-812
A critical site in the core of the CCR5 chemokine receptor required for binding and infectivity of human immunodeficiency virus type 1
Authors: Siciliano, SJ Kuhmann, SE Weng, YM Madani, N Springer, MS Lineberger, JE Danzeisen, R Miller, MD Kavanaugh, MP DeMartino, JA Kabat, D
Citation: Sj. Siciliano et al., A critical site in the core of the CCR5 chemokine receptor required for binding and infectivity of human immunodeficiency virus type 1, J BIOL CHEM, 274(4), 1999, pp. 1905-1913
Risultati: 1-10 |